Cross-reactive skin eruption with both carbamazepine and oxcarbazepine

Epilepsia. Jan-Feb 1993;34(1):163-5. doi: 10.1111/j.1528-1157.1993.tb02392.x.

Abstract

Oxcarbazepine (OCBZ), a 10-keto derivative of carbamazepine (CBZ) has been reported to have a similar range of efficacy and fewer unwanted effects than CBZ since it is a prodrug for the monohydroxy derivative (MHD). A cross-reactivity of only 1 in 4 has been reported between OCBZ and CBZ. For these reasons, we tried OCBZ with 3 consecutive patients with poorly controlled epilepsy who had had a therapeutic response to CBZ but in whom CBZ was discontinued because of serious skin reaction. Each patient had a similar skin response after exposure to only 600-900 mg OCBZ, which suggests a need to practice caution when substituting OCBZ for CBZ in patients known to have serious skin reaction to CBZ.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Carbamazepine / adverse effects*
  • Carbamazepine / analogs & derivatives*
  • Dermatitis, Exfoliative / chemically induced
  • Drug Eruptions / etiology*
  • Epilepsy / drug therapy*
  • Humans
  • Male
  • Oxcarbazepine

Substances

  • Carbamazepine
  • Oxcarbazepine